Cybin Set to Launch Pivotal Phase 3 Depression Study
Company Announcements

Cybin Set to Launch Pivotal Phase 3 Depression Study

Story Highlights

Cybin (TSE:CYBN) has released an update.

Cybin Inc. is on the brink of starting a major Phase 3 clinical study for its CYB003 drug aimed at treating Major Depressive Disorder, with expectations of releasing 12-month efficacy data from its Phase 2 study by early Q4 2024. Additionally, the company anticipates year-end 2024 or early Q1 2025 to unveil topline efficacy and safety results for CYB004 in treating Generalized Anxiety Disorder, backed by newly appointed experienced leaders in drug development.

For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.

Related Articles
Ryan AdistCYBN Upcoming Earnings Report: What to Expect?
TipRanks Canadian Auto-Generated NewsdeskCybin to Highlight Innovations at Health Summit
TheFlyRising High: RIV Capital provides update on revenue, synergy realization
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App